Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 10/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sibrafiban SCHEMBL27618015 | 1.00 | ITGB3 (1.00) | ITGB3ITGA2BF2LMNAPOLB | |
| SCHEMBL6947214 | 0.88 | ITGB3 (1.00) | ITGB3ITGA2BPOLB | |
| SCHEMBL7285318 | 0.88 | ITGB3 (1.00) | ITGB3ITGA2BPOLB | |
| SCHEMBL7285305 | 0.88 | ITGB3 (1.00) | ITGB3ITGA2BPOLB | |
| SCHEMBL6947203 | 0.88 | ITGB3 (1.00) | ITGB3ITGA2BPOLB | |
| SCHEMBL7284599 | 0.85 | ITGB3 (0.74) | ITGB3ITGA2BF2LMNASMYD3 | |
| SCHEMBL27544859 | 0.85 | ITGB3 (0.74) | ITGB3ITGA2BF2POLBSMYD3 | |
| SCHEMBL27403694 | 0.85 | ITGB3 (0.74) | ITGB3ITGA2BF2POLBSMYD3 | |
| SCHEMBL8645304 | 0.84 | ITGB3 (0.73) | ITGB3ITGA2BLMNAPOLBSMYD3 | |
| SCHEMBL8379150 | 0.83 | ITGB3 (0.82) | ITGB3ITGA2BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584131-B2 | Methods of gene therapy | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2026-03-24 | — | — | US | claimed |
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4439040-A2 | HEPARIN-BASED BLOOD SAMPLER WITHOUT PLATELET ACTIVATION | Radiometer Medical ApS (DK) | 2024-10-02 | — | — | EP | claimed |
| EP-3154343-B1 | RODENT BAIT CONTAINING TWO OR MORE ANTICOAGULATING COMPOUNDS | GULBA DIETRICH (DE) | 2023-10-25 | — | — | EP | claimed |
| US-20230190499-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-22 | — | — | US | claimed |
| US-11421234-B2 | Aptamers for targeting coagulation factor XIII and uses thereof | CHANG GUNG UNIVERSITY (TW) | 2022-08-23 | — | — | US | claimed |
| US-20210163945-A1 | APTAMERS FOR TARGETING COAGULATION FACTOR XIII AND USES THEREOF | CHANG GUNG UNIVERSITY (TW) | 2021-06-03 | — | — | US | claimed |
| US-20200393345-A1 | HEPARIN-BASED BLOOD SAMPLER WITHOUT PLATELET ACTIVATION | RADIOMETER MEDICAL APS (DK) | 2020-12-17 | — | — | US | claimed |
| EP-3710806-A1 | HEPARIN-BASED BLOOD SAMPLER WITHOUT PLATELET ACTIVATION | Radiometer Medical ApS (DK) | 2020-09-23 | — | — | EP | claimed |
| EP-2214573-B1 | SYSTEM FOR TREATMENT AND IMAGING USING ULTRASONIC ENERGY AND MICROBUBBLES | UNIV VIRGINIA PATENT FOUNDATION (US) | 2019-07-03 | — | — | EP | claimed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-20020068719-A1 | Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-06 | — | — | US | claimed |
| EP-1189663-A2 | SYNERGY BETWEEN LOW MOLECULAR WEIGHT HEPARIN AND PLATELET AGGREGATION INHIBITORS, FOR PREVENTING AND TREATING THROMBOEMBOLIC DISORDERS | Du Pont Pharmaceuticals Company (US) | 2002-03-27 | — | — | EP | claimed |
| US-6346517-B1 | ADMINISTERING TINZAPARIN AND ROXIFIBAN | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-12 | — | — | US | claimed |
| US-20010036913-A1 | Combination therapy for reducing the risks associated with cardiovascular disease | GOULD ROBERT J (US) | 2001-11-01 | — | — | US | claimed |
| US-6251852-B1 | SUCH AS ACUTE CORONARY ISCHEMIC SYNDROME AND Q-WAVE MYOCARDIAL INFARCTION, BY ADMINISTERING A 3-HYDROXY-3-METHYLGLUTARYL COENZYME A (HMG-COA) REDUCTASE INHIBITOR IN COMBINATION WITH A PLATELET AGGREGATION INHIBITOR | MERCK & CO., INC. | 2001-06-26 | — | — | US | claimed |
| US-6235706-B1 | Combination therapy for reducing the risks associated with cardiovascular disease | MERCK & CO., INC. | 2001-05-22 | — | — | US | claimed |
| WO-2000053168-A2 | SYNERGY BETWEEN LOW MOLECULAR WEIGHT HEPARIN AND PLATELET AGGREGATION INHIBITORS, FOR PREVENTING AND TREATING THROMBOEMBOLIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-09-14 | — | — | WO | claimed |
| EP-0946178-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | Merck & Co., Inc. (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1998011896-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | MERCK & CO., INC. (US) | 1998-03-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068719-A1 | Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders | SERPINC1, SELP, F13B | ITGB3 30/4885ITGA2B 20/4885F2 116/4885 |
| US-20010036913-A1 | Combination therapy for reducing the risks associated with cardiovascular disease | HMGCR, PCSK9, APOB | ITGB3 699/4885ITGA2B 740/4885F2 37/4885 |
| US-12584131-B2 | Methods of gene therapy | CYP7A1, POR, CYP4A22 | ITGB3 3772/4885ITGA2B 2294/4885F2 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.